58 related articles for article (PubMed ID: 8632425)
1. Endogenous natriuretic factors. 5. Synthesis and biological activity of a natriuretic metabolite of diltiazem and its derivatives.
Kantoci D; Murray ED; Quiggle DD; Wechter WJ
J Med Chem; 1996 Mar; 39(6):1196-1200. PubMed ID: 8632425
[TBL] [Abstract][Full Text] [Related]
2. Endogenous natriuretic factors 3: isolation and characterization of human natriuretic factors LLU-alpha, LLU-beta 1, and LLU-gamma.
Murray ED; Kantoci D; DeWind SA; Bigornia AE; D'Amico DC; King JG; Pham T; Levine BH; Jung ME; Wechter WJ
Life Sci; 1995; 57(23):2145-61. PubMed ID: 7475967
[TBL] [Abstract][Full Text] [Related]
3. Endogenous natriuretic factors 7: biospecificity of a natriuretic gamma-tocopherol metabolite LLU-alpha.
Murray ED; Wechter WJ; Kantoci D; Wang WH; Pham T; Quiggle DD; Gibson KM; Leipold D; Anner BM
J Pharmacol Exp Ther; 1997 Aug; 282(2):657-62. PubMed ID: 9262327
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of clentiazem in rats.
Nakamura S; Sugawara Y; Fukushima T; Ito Y; Ohashi M; Takaiti O
Biol Pharm Bull; 1993 Jul; 16(7):635-46. PubMed ID: 8401395
[TBL] [Abstract][Full Text] [Related]
5. A new endogenous natriuretic factor: LLU-alpha.
Wechter WJ; Kantoci D; Murray ED; D'Amico DC; Jung ME; Wang WH
Proc Natl Acad Sci U S A; 1996 Jun; 93(12):6002-7. PubMed ID: 8650209
[TBL] [Abstract][Full Text] [Related]
6. Endogenous natriuretic factors 6: the stereochemistry of a natriuretic gamma-tocopherol metabolite LLU-alpha.
Kantoci D; Wechter WJ; Murray ED; Dewind SA; Borchardt D; Khan SI
J Pharmacol Exp Ther; 1997 Aug; 282(2):648-56. PubMed ID: 9262326
[TBL] [Abstract][Full Text] [Related]
7. High-affinity binding of DTZ323, a novel derivative of diltiazem, to rabbit skeletal muscle L-type Ca++ channels.
Hagiwara M; Adachi-Akahane S; Nagao T
J Pharmacol Exp Ther; 1997 Apr; 281(1):173-9. PubMed ID: 9103495
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular characterization of pyrrolo[2,1-d][1,5]benzothiazepine derivatives binding selectively to the peripheral-type benzodiazepine receptor (PBR): from dual PBR affinity and calcium antagonist activity to novel and selective calcium entry blockers.
Campiani G; Fiorini I; De Filippis MP; Ciani SM; Garofalo A; Nacci V; Giorgi G; Sega A; Botta M; Chiarini A; Budriesi R; Bruni G; Romeo MR; Manzoni C; Mennini T
J Med Chem; 1996 Jul; 39(15):2922-38. PubMed ID: 8709127
[TBL] [Abstract][Full Text] [Related]
9. Diltiazem-like calcium entry blockers: a hypothesis of the receptor-binding site based on a comparative molecular field analysis model.
Corelli F; Manetti F; Tafi A; Campiani G; Nacci V; Botta M
J Med Chem; 1997 Jan; 40(1):125-31. PubMed ID: 9016337
[TBL] [Abstract][Full Text] [Related]
10. Sequential metabolism is responsible for diltiazem-induced time-dependent loss of CYP3A.
Zhao P; Lee CA; Kunze KL
Drug Metab Dispos; 2007 May; 35(5):704-12. PubMed ID: 17293381
[TBL] [Abstract][Full Text] [Related]
11. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation.
Jones DR; Gorski JC; Hamman MA; Mayhew BS; Rider S; Hall SD
J Pharmacol Exp Ther; 1999 Sep; 290(3):1116-25. PubMed ID: 10454485
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and pharmacological activities of some 2,3,4,5-tetrahydro[1,5]benzo[f]thiazepines.
Saturnino C; Saturnino P; De Martino G; Lancelot JC; Perrine D; Rault S; Robba M; Rossi F
Farmaco; 1997 Mar; 52(3):183-6. PubMed ID: 9212453
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and antihypertensive activity of 3-acetoxy-2,3-dihydro-5-[2- (dimethylamino)ethyl]-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one (diltiazem) derivatives having substituents at the 8 position.
Yanagisawa H; Fujimoto K; Shimoji Y; Kanazaki T; Mizutari K; Nishino H; Shiga H; Koike H
Chem Pharm Bull (Tokyo); 1992 Aug; 40(8):2055-61. PubMed ID: 1423759
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological testing of thiosalicylamides as a novel class of calcium channel blockers.
Mehanna AS; Kim JY
Bioorg Med Chem; 2005 Jul; 13(13):4323-31. PubMed ID: 15927838
[TBL] [Abstract][Full Text] [Related]
15. Competitive and cooperative effects of Bay K8644 on the L-type calcium channel current inhibition by calcium channel antagonists.
Zahradníková A; Minarovic I; Zahradník I
J Pharmacol Exp Ther; 2007 Aug; 322(2):638-45. PubMed ID: 17475903
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, characterization, and Ca2+ antagonistic activity of diltiazem metabolites.
Li R; Farmer PS; Xie M; Quilliam MA; Pleasance S; Howlett SE; Yeung PK
J Med Chem; 1992 Aug; 35(17):3246-53. PubMed ID: 1507210
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of the metabolites of clentiazem.
Inoue H; Nakamura S; Otsuka H; Gaino M; Harada T; Matsuki K; Takeda M
Chem Pharm Bull (Tokyo); 1994 Jan; 42(1):167-72. PubMed ID: 8124760
[TBL] [Abstract][Full Text] [Related]
18. Metabolism of diltiazem. I. Structures of new acidic and basic metabolites in rat, dog and man.
Sugawara Y; Ohashi M; Nakamura S; Usuki S; Suzuki T; Ito Y; Kume T; Harigaya S; Nakao A; Gaino M
J Pharmacobiodyn; 1988 Apr; 11(4):211-23. PubMed ID: 3411439
[TBL] [Abstract][Full Text] [Related]
19. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A.
Ma B; Prueksaritanont T; Lin JH
Drug Metab Dispos; 2000 Feb; 28(2):125-30. PubMed ID: 10640508
[TBL] [Abstract][Full Text] [Related]
20. L-Type calcium channel blockers: from diltiazem to 1,2,4-oxadiazol-5-ones via thiazinooxadiazol-3-one derivatives.
Budriesi R; Cosimelli B; Ioan P; Ugenti MP; Carosati E; Frosini M; Fusi F; Spisani R; Saponara S; Cruciani G; Novellino E; Spinelli D; Chiarini A
J Med Chem; 2009 Apr; 52(8):2352-62. PubMed ID: 19323482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
